MARC HASENFUSS: Rockets and wild riffs
The share price of Ascendis took off like a Benzedrine addict being chased by a rabid Doberman
Plague diary, week four: This entry has been abridged by the lockdown’s long weekend, but it was, I’m delighted to report, a short and spectacular session. Not only was the veggie patch not violated by the pesky primates (whereabouts, at the time of writing, unknown), but I had a rare rocket in the portfolio.
The share price of pharmaceuticals group Ascendis — where I have dosed up and down in recent weeks — took off like a Benzedrine addict being chased by a rabid Doberman.